Summary
Aurobindo Pharma, through its Lannett Company, has launched a generic version of Advair Diskus in the US for asthma and COPD, marking its first complex inhalation product in the market. This launch, into a market worth approximately $908 million, coincides with Cipla's US branch also receiving FDA approval for the same product, setting up competition in respiratory treatments.
Aurobindo's Lannett Launches Generic Version of GSK Drug in US
15 Sept 2026, 5:05 am · News
Aurobindo Pharma Gains Over 3% as Subsidiary Launches Generic Advair Diskus in US
15 Sept 2026, 5:05 am · News
USFDA Concludes Inspection of Aurobindo Pharma Subsidiary with 4 Observations
15 Sept 2026, 5:05 am · News
Turn this story into an image post, carousel, video, audio reel, blog, and more — all from HyperFast News.
Pick a story, apply your brand template, and publish polished graphics to Facebook, Instagram, LinkedIn, and more — without opening a design tool.
Create Image PostDescribe the story, headline, colors, and style you want.
Try Prompt to PostCombine branded news graphics with narration — from your audio library, a live recording, or AI text-to-speech — and share as engaging short-form content.
Create Audio PostUpload your footage, apply a video template with baked-in headlines, add optional audio, and schedule posts across every connected social channel.
Create Video PostCombine several news items into a single swipeable carousel post — with a shared title, unified caption, and per-slide template content for maximum engagement.
Create CarouselUpload your media, craft the perfect caption with AI assistance, preview on every platform, and schedule posts for the exact moment your audience is online.
Schedule a PostTransform breaking news into long-form, SEO-optimized blog posts with AI writing, a rich text editor, featured images, and one-click social image post creation.
Create Blog PostTurn any news article into a professional anchor video with AI-generated presenters, natural voice narration, and lip-sync animation — no studio, no crew, no wait.
Learn moreAbout the public HyperFast News news feed powered by NewsEngine.
